Ovarian epithelial tumor
MONDO:0002229A benign, borderline, or malignant tumor that originates from the surface epithelium of the ovary. It is composed of epithelial cells and stroma. Representative examples of benign tumors include serous cystadenoma, mucinous cystadenoma, and benign Brenner tumor. Representative examples of borderline tumors include serous surface papillary tumor, mucinous adenofibroma, and borderline Brenner tumor. Representative examples of malignant tumors include serous adenocarcinoma, mucinous adenocarcinoma, endometrioid adenocarcinoma, and malignant Brenner tumor.
Also known as: epithelial neoplasm of ovary, epithelial neoplasm of the ovary, epithelial tumor of ovary, epithelial tumor of the ovary, epithelial tumour of ovary, epithelial tumour of the ovary, ovarian epithelial tumor, ovarian surface epithelial-stromal tumor
2048 clinical trials for this condition and its sub-types, 14 tagged with Ovarian epithelial tumor itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Ovarian epithelial tumor
-
Malignant epithelial tumor of ovary 8 trials · 656 incl. sub-types
6 sub-types
- Ovarian carcinoma 493 trials · 642 incl. sub-types Sub-types →
- Malignant ovarian serous tumor 5 trials · 203 incl. sub-types Sub-types →
- Ovarian endometrial cancer 4 trials · 89 incl. sub-types Sub-types →
- Ovarian clear cell cancer 30 trials · 51 incl. sub-types Sub-types →
- Mucinous ovarian cancer 2 trials · 16 incl. sub-types Sub-types →
- Malignant ovarian Brenner tumor 2 trials
-
Ovarian serous tumor 6 trials · 208 incl. sub-types
2 sub-types
- Malignant ovarian serous tumor 5 trials · 203 incl. sub-types Sub-types →
- Borderline ovarian serous tumor 11 trials
-
Ovarian clear cell tumor 7 trials · 57 incl. sub-types
1 sub-type
- Ovarian clear cell cancer 30 trials · 51 incl. sub-types Sub-types →
-
Borderline epithelial tumor of ovary 6 trials · 16 incl. sub-types
1 sub-type
- Borderline ovarian serous tumor 11 trials
-
Ovarian mucinous neoplasm 1 trial · 16 incl. sub-types
2 sub-types
- Mucinous ovarian cancer 2 trials · 16 incl. sub-types Sub-types →
- Benign ovarian mucinous tumor 0 trials
-
Ovarian seromucinous tumor 1 trial · 14 incl. sub-types
1 sub-type
- Ovarian seromucinous carcinoma 13 trials
-
Ovarian Brenner tumor 3 trials · 5 incl. sub-types
1 sub-type
- Malignant ovarian Brenner tumor 2 trials
-
Ovarian papillary tumor 0 trials · 2 incl. sub-types
3 sub-types
- Ovarian serous surface papillary adenocarcinoma 2 trials
- Ovarian papillary cystadenoma 0 trials
- Ovarian surface papilloma 0 trials
-
Ovarian squamous cell neoplasm 0 trials · 2 incl. sub-types
1 sub-type
- Ovarian squamous cell carcinoma 2 trials
-
Ovarian adenoma benign 0 trials
2 sub-types
- Ovarian cystadenoma 0 trials Sub-types →
- Rete ovarii adenoma 0 trials Sub-types →
-
Ovarian mucinous adenofibroma 0 trials
1 sub-type
- Ovarian mucinous cystadenofibroma 0 trials
Most studied deeper sub-types
-
Can engineered immune cells outsmart Drug-Resistant ovarian cancer?
Cure OngoingThis phase 1 trial tests an experimental therapy called AB-1015 in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. AB-1015 uses a patient's own T cells, which are genetically engineered to recognize and…
Phase 1 • Sponsor: Arsenal Biosciences, Inc. • Aim: Cure
Last updated Sep 05, 2026 00:00 UTC
-
Ovarian cancer combo shows promise in maintenance therapy
Disease control OngoingThis phase IV trial tests whether the drugs olaparib and bevacizumab, taken together after initial chemotherapy, can help prevent ovarian cancer from coming back in women with a specific genetic marker (HRD-positive). About 190 participants who have already responded to first-lin…
Phase 4 • Sponsor: Mario Negri Institute for Pharmacological Research • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental antibody boosts chemo in ovarian cancer trial
Disease control OngoingThis phase 2 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps control advanced ovarian, fallopian tube, or peritoneal cancer better than chemo alone. About 88 women with newly diagnosed stage III or …
Phase 2 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer hope: new antibody combo aims to delay disease worsening
Disease control OngoingThis Phase 3 trial tests whether adding an experimental antibody called oregovomab to standard chemotherapy (paclitaxel and carboplatin) helps people with newly diagnosed advanced ovarian cancer live longer without their cancer getting worse. About 615 participants who had surger…
Phase 3 • Sponsor: CanariaBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Ovarian cancer trial hopes immunotherapy can buy more time
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (paclitaxel, with or without bevacizumab) can slow the growth of ovarian cancer that has become resistant to platinum-based treatments. About 643 adults with recurrent ovarian, fallopian…
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Mushroom extract tested to ease chemo side effects in ovarian cancer
Symptom relief OngoingThis pilot study tests whether a supplement called AHCC, made from cultured mushroom mycelia, can improve quality of life for ovarian cancer patients receiving standard chemotherapy. About 20 participants will take either AHCC or a placebo during their treatment. The main goal is…
Phase 2 • Sponsor: University of California, Davis • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Ovarian tumor genes may reveal who needs stronger treatment
Knowledge-focused OngoingThis study examines genetic mutations in 20 people with serous borderline ovarian tumors, a low-risk type of ovarian growth. Researchers compare tumors with and without implants (spread) to see if certain gene changes predict a higher chance of recurrence. The goal is to learn wh…
Sponsor: Universitair Ziekenhuis Brussel • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC